EUVIMEDEUVIMED entdecken
Open Access

Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?

Fengna Chu iD, Mingchao Shi, Canyun Liu, Jie Zhu

Clinical and Experimental Immunology · 2023

DOI: 10.1093/cei/uxad053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2023. Verfasst von Fengna Chu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Aquaporin 4, Autoantibodies, Blood-Brain Barrier, Immunoglobulin G. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AQP4-IgG has been considered as the pathogenic factor leading to NMOSD. However, about 20–30% of patients lack AQP4-IgG. So far, all therapeutic medicines are ineffective for NMOSD patients without AQP4 IgG. Thus AQP4-IgG is the pathogenic factor of NMOSD has been suspected and challenged. In addition, lack of efficacy of immunotherapy in NMOSD without AQP4 IgG has been a serious problem in the neurology. Identifying the clinical and laboratory characteristics and diversities between NMOSD patients with and without AQP4-IgG can be helpful to further explore the pathogenesis of NMOSD and guide clinical treatment. This is a single-centre retrospective study in The First Hospital of Jilin University, China including 92 patients diagnosed as NMOSD from January 2013 to January 2015. The characteristics of clinic, blood, cerebrospinal fluid (CSF), and image between AQP4-IgG negative (AQP4-IgG−) and AQP4-IgG positive (AQP4-IgG+) NMOSDs were compared. Our results showed that in the AQP4-IgG+ group, the ratio of women to men was 5.55, while in AQP4-IgG− group was 1.54 (P = 0.0092). In the AQP4-IgG+ patients, the expanded disability status scale (EDSS) was from 0 to 8.5, with an average of 5.550 ± 0.25, and the AQP4-IgG− patients had the EDSS score from 0 to 9, with an average of 4.032 ± 0.36 (P = 0.0006), which mainly affected movement system (P < 0.05) and superficial sensory impairment (P < 0.05). In the AQP4-IgG+ group, the blood brain barrier (BBB) permeability (P = 0.0210) and myelin basic protein (MBP) were increased (P = 0.0310) when compared to AQP4-IgG− group. Higher level IL-17 was seen in AQP4-IgG+ group than AQP4-IgG− group (P= 0.0066). Our results demonstrated that the NMOSD with AQP4-IgG more likely occurred in women and presented more severe clinical symptoms as well as significant BBB damage and increased MBP and IL-17 in CSF and blood, respectively compared with NMOSD without AQP4-IgG group. The differences in clinical and laboratory profiles between NMOSD with and without AQP4-IgG indicate the heterogeneity of NMOSD, in which AQP4-IgG may not be the only pathogenic molecule. It is necessary to find more pathogenic factors and to explore the new pathogenesis of NMOSD and therapeutic methods in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aquaporin 4AutoantibodiesBlood-Brain BarrierImmunoglobulin GNeuromyelitis OpticaAdultFemaleHumansMaleRetrospective Studies

Stichwörter der Autor:innen

AQP4 antibodyautoimmune diseasecomplement C5iinterleukin-17neuromyelitis optica spectrum disorder

Substanzen

AQP4 protein, humanAquaporin 4AutoantibodiesImmunoglobulin G

Autor:innen und Institutionen

  • Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China.
  • Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrics, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.

ORCID-Profile: Fengna Chu

Zitieren

APA

Chu, F., Shi, M., Liu, C., & Zhu, J. (2023). Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad053

Vancouver

Chu F, Shi M, Liu C, Zhu J. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?. Clinical and Experimental Immunology. 2023. doi:10.1093/cei/uxad053

BibTeX
@article{Chu2023,
  author = {Chu, Fengna and Shi, Mingchao and Liu, Canyun and Zhu, Jie},
  title = {Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?},
  journal = {Clinical and Experimental Immunology},
  year = {2023},
  doi = {10.1093/cei/uxad053}
}
Kostenlos starten →